A5058842585- Psoriasis: Treatment and Pathogenesis
- Dermatology and Skin Diseases
- Autoimmune Bullous Skin Diseases
- Asthma and respiratory diseases
- Cutaneous Melanoma Detection and Management
- Allergic Rhinitis and Sensitization
- Health Systems, Economic Evaluations, Quality of Life
- Dermatological and COVID-19 studies
- COVID-19 and healthcare impacts
- Cutaneous lymphoproliferative disorders research
- Urticaria and Related Conditions
- Cytokine Signaling Pathways and Interactions
- Nonmelanoma Skin Cancer Studies
- Spondyloarthritis Studies and Treatments
- Autoimmune and Inflammatory Disorders
- Autoimmune and Inflammatory Disorders Research
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Melanoma and MAPK Pathways
- Hidradenitis Suppurativa and Treatments
- Colorectal and Anal Carcinomas
- Fibromyalgia and Chronic Fatigue Syndrome Research
- Chemotherapy-related skin toxicity
- Health disparities and outcomes
- Dermatologic Treatments and Research
IRCCS Humanitas Research Hospital
2022-2025
Humanitas University
2019-2025
Sapienza University of Rome
2023
Istituti di Ricovero e Cura a Carattere Scientifico
2019-2021
Vita-Salute San Raffaele University
2015
Abstract Background Tirbanibulin 1% ointment is approved for the field treatment of Olsen grade I actinic keratoses (AKs) face and scalp. Methods We performed a multicenter retrospective study involving 15 dermatologic units in Italy to investigate efficacy tolerability tirbanibulin real‐life setting. 250 patients were enrolled. Tirbanibulin, ointment, was applied daily five consecutive days. The measured with modifications Actinic Keratosis Area Severity Index (AKASI). A satisfactory...
Background: Interleukin (IL) inhibitors are increasingly used in the management of moderate-to-severe plaque psoriasis. However, their use patients with a history cancer is debated.
Vismodegib and sonidegib are smoothened (SMO) inhibitors approved for the treatment of advanced basal cell carcinoma (aBCC). This study investigates real-world experiences outcomes associated with these therapies across multiple Italian centers. A retrospective, observational, multicenter was conducted. Medical records patients local (laBCC) treated SMO outside clinical trials from July 2019 to April 2024 were analyzed. total 57 included in study, 19 (33.3%) receiving vismodegib 38 (66.7%)...
Janus kinase (JAK) inhibitors are widely used for treating atopic dermatitis (AD) and alopecia areata (AA). Weight gain is an emergent adverse event associated with JAK inhibitors, particularly those acting on the JAK2 pathway. We conducted a retrospective monocentric 2-cohort study, including 226 patients, to evaluate prevalence of weight in patients AD AA who were treated at least one year. included 142 JAK1/2 cohort (receiving upadacitinib 30 mg or baricitinib 4 mg) 84 JAK1 15 abrocitinib...
Tildrakizumab is a humanized monoclonal antibody that binds selectively the p19 subunit of interleukin-23. It approved for treatment moderate-severe chronic plaque psoriasis.We conducted 52-week retrospective study to assess effectiveness and safety tildrakizumab in real-life setting.Our included 237 consecutive adults with moderate-to-severe psoriasis, enrolled 10 different Italian centres, treated up Week 52. Patient characteristics, comorbidities, previous treatments PASI (Psoriasis Area...
Risankizumab is a humanized monoclonal antibody that selectively targets interleukin-23. It approved for treatment of moderate-to-severe plaque psoriasis. We conducted 52-week monocentric retrospective study to evaluate the effectiveness and safety risankizumab in real-life setting. Our included 131 adults with psoriasis all treated at least 52 weeks. Patient characteristics PASI (Psoriasis Area Severity Index) each visit were recorded. The percentages patients achieving 75%/90%/100% (PASI...
The treatment of severe atopic dermatitis (AD) includes cyclosporine and recently approved biologics small molecules. Among these, upadacitinib is a selective inhibitor Janus kinase 1, for the AD in adolescents/adults. Upadacitinib has shown efficacy safety several phase 3 clinical trials, but data on real-life patients are still lacking. We conducted retrospective observational study to evaluate effectiveness up week 16 cohort both bio-naïve bio-experienced patients. This was carried out by...
Background: Risankizumab is a humanized monoclonal antibody that selectively inhibits interleukin-23. It has been approved for moderate-to-severe plaque psoriasis and shown efficacy safety in clinical trials real-world experiences. This study aimed to evaluate the long-term effectiveness, safety, drug survival of risankizumab real-life setting. Materials Methods: We included patients treated with from January 2019 February 2023. A Psoriasis Area Severity Index score (PASI) was collected at...
The COVID-19 pandemic required the setting of a national lockdown in Italy from March 9, 2020, until May 18, 2020; therefore, most non-COVID-19 activities were postponed. As consequence, many follow-up visits patients with previously excised skin cancers delayed. aim this retrospective real-life case-control study is demonstrating that delay led to an increased incidence advanced melanoma and keratinocyte on total surgically cancers.The our dermato-surgery division period 18 November was...
Risankizumab is a humanized monoclonal antibody that binds the p19 subunit of interleukin-23. It approved for treatment moderate-severe chronic plaque psoriasis. This retrospective study included 66 consecutive adults with moderate-to-severe psoriasis vulgaris treated risankizumab in monotherapy up to week 40 "real-life" setting. At 40, 98.7%, 85.7% and 62.3% patients achieved Psoriasis Area Severity Index (PASI) reduction ≥ 75% (PASI 75), PASI 90 100, respectively. Patients who had not...
The management of plaque psoriasis that affects difficult-to-treat areas can be challenging. Biologics have become the treatment choice for moderate-to-severe psoriasis. However, there are limited data on their efficacy in sites (including scalp, palms/soles, nails and genitalia). We conducted a 52-week retrospective study to evaluate effectiveness risankizumab 202 patients with involvement at least one area. One hundred sixty-five had scalp psoriasis, 21 palms or soles, 72 were affected by...
Biological drugs have dramatically changed the approach to treating moderate-to-severe plaque psoriasis, achieving excellent skin clearance and safety outcomes. However, management of difficult-to-treat areas (e.g., scalp, palms/soles, nails, genitalia) still represents a challenge in psoriasis treatment. Data literature on sites are limited and, frequently, no specific analysis is performed during clinical trials. We conducted 52-week, retrospective study evaluate effectiveness ixekizumab...
Purpose Tildrakizumab is a selective inhibitor of IL-23 approved for the treatment moderate-to-severe plaque psoriasis in two dosages. We conducted 16-week multicenter retrospective study to compare effectiveness and safety tildrakizumab 200 mg versus 100 patients with high disease burden or body weight.
Background Genital involvement in atopic dermatitis(AD) can have a significant impact on the patient's quality of life. However, inspection genital areas is not usually conducted during routine examination and patients may be reluctant to inform clinician or show this area.
Scalp is a frequent localization of psoriasis that has massive impact on patient's quality life. Managing this psoriasis' manifestation often challenging, thus biologic drugs are widely used as treatment option in refractory scalp psoriasis. The aim our study to retrospectively compare the efficacy anti-interleukin (IL) 23 (guselkumab, tildrakizumab, risankizumab) and anti-IL17 or anti-IL17RA biologics (secukinumab, ixekizumab, brodalumab) real-life patients affected by One hundred...
There are no strong data regarding the treatment with biologics (especially for most recent anti-IL-17 and anti-IL-23 drugs) of patients psoriasis concomitant viral hepatitis. We assessed safety biologic drugs in who seropositive hepatitis B or C did not receive antiviral prophylaxis. conducted a retrospective single-center study. The efficacy treatments was evaluated by assessing Psoriasis Area Severity Index (PASI) score during all visits, minimum follow-up 52 weeks. All were hepatologist...
The introduction of biological therapies has revolutionized the treatment moderate-to-severe plaque psoriasis. In particular, ixekizumab, an inhibitor interleukin-17A, shown great results in terms efficacy and safety both clinical trials real-world experiences. However, there is a lack long-term data available for ixekizumab. We conducted multicenter real-life study to evaluate effectiveness ixekizumab patients with Psoriasis Area Severity Index score (PASI) was collected at baseline after...